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economic analysis of the HomePAP study, a multi-center randomized clinical trial
that compared home-based versus lab-based testing for themanagement of OSA in
accredited sleep centers. METHODS: A total of 373 subjects with a high risk for
moderate to severe OSA were randomized to either unattended, home-based lim-
ited channel portable monitoring for diagnosis of OSA followed by unattended
auto-titration with continuous positive airway pressure (CPAP), versus a tra-
ditional pathway of in-laboratory sleep study and CPAP titration. Given that 3
month outcomes were not inferior for the home arm in acceptance, adherence,
and functional improvements, we pursued a cost minimization analysis from
the payer perspective. 2011 Medicare price weights were used. Interpretation of
home-based CPAP titration is currently not reimbursed by Medicare, so we es-
timated it as one-third the Medicare reimbursement for interpreting a lab-based
sleep study. RESULTS: Per subject costs, as randomized, were $1265 for the lab-
based pathway and $927 for the home-based pathway (base case). In the per pro-
tocol analysis (patients adherent to CPAP for 3months), per subject costswere even
higher for the lab-based pathway ($1,863 vs. $866). In a sensitivity analysis, even
after increasing the Medicare reimbursement for home-based titration studies to
100% that of lab-based studies, per subject costs per protocol were still higher for
the lab-based pathway ($1,863 vs. $953). CONCLUSIONS: From the payer perspec-
tive, there are higher costs incurred within a lab-based versus a home-based diag-
nostic pathwaywithout superiority in outcomes. The results suggest that the care-
ful use of home-based sleep studies administered by trained personnel at board-
certified sleep centers could save money without compromising short term
outcomes.
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OBJECTIVES: Improvement in glycaemic control associated with Continuous Glu-
cose Monitoring (CGM) use leads to a reduction of costly diabetes-related compli-
cations. Our aim was to estimate the health economics benefits of CGM compared
to Self-Monitoring of Blood Glucose (SMBG) in type 1 diabetes (T1DM) in the Swed-
ish setting.METHODS: The Core DiabetesModel (CDM) is an internet-based, highly
validated, computer-simulation model to determine the long-term health out-
comes and economic consequences of diabetes interventions. This model was
used to evaluate the cost-effectiveness of CGM versus SMBG in T1DM over a life-
time horizon. Results from a recently published meta-analysis comparing CGM
versus SMBG and a real life observational Swedish study were used. The meta-
analysis showed that for a cohort of T1DM with average baseline HbA1c of 8.1%,
mean baseline age of 27 years and diabetes duration of 13 years, everyday use of
CGM led to HbA1c reduction of -0.76% versus -0.13%, for CGM and SMBG respec-
tively. The observational study demonstrated a reduction from 7.11 to 4.35 daily
blood glucose tests when using CGM compared to SMBG only. RESULTS: The Incre-
mental-Cost-Effectiveness-Ratio (ICER) for CGM vs. SMBG only was 369,253SEK
(41,940€) per Quality-Adjusted-Life-Year gained (QALYg), based on combined direct
and indirect costs. Undiscounted life expectancy was improved by 1.5 years. The
improvement in discounted QALY was 0.62 in favour of CGM. CGM related costs
were partially offset by the savings due to the reduction in long-term complica-
tions. CGM usage compared to SMBG increased the mean time alive free from
complications. Sensitivity analysis has been conducted. CONCLUSIONS: Our anal-
ysis showed that CGM is very cost-effective compared to SMBG over a lifetime
horizon in T1DM patients in the Swedish setting and can lead to an increase in life
expectancy.
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OBJECTIVES: To estimate the cost-effectiveness of delayed troponin testing for
myocardial infarction (MI), as recommended in current guidelines, compared to
troponin testing at presentation. METHODS: We developed a decision analytic
model to estimate the cost-effectiveness of diagnostic strategies for MI, measured
as the incremental cost per quality-adjusted life year (QALY) gained by each strat-
egy compared to the next most effective alternative. The model was applied to a
hypothetical population of 1000 patients attending hospital with symptoms sug-
gesting MI but a normal or non-diagnostic electrocardiogram (ECG) and no major
co-morbidities requiring hospital treatment. Delayed troponin testing (10-12 hours
after symptom onset) was compared to standard and high sensitivity troponin
testing at presentation and no testing. We tested three different scenarios regard-
ing delayed testing, in relation to the delay between results being available and a
decision beingmade, the “doctor on demand” scenario, inwhichmedical staffwere
available 24 hours a day to make a disposition decision within one hour of the
results being available, twice daily ward round and once daily ward round scenar-
ios where medical staff were only available at twice daily ward rounds and once
dailyward rounds, respectively. RESULTS: In all scenarios tested presentation high
sensitivity troponin testing was the most effective strategy with an incremental
cost-effectiveness ratio (ICER) below the £20,000/QALY threshold. Delayed tro-
ponin testing was only likely to be cost-effective if a discharge decision could be
made as soon as a negative result was available and the £30,000/QALY threshold
was used. CONCLUSIONS: Delayed troponin testing is unlikely to be cost-effective
compared to high sensitivity troponin testing at presentation in most scenarios.
The current guidelines recommending 10-12 hour troponin testing does not appear
to promote cost-effective use of hospital resources, unless services are in place to
allow rapid decision making once delayed test results are available.
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OBJECTIVES: To estimate the clinical and economic consequences of Continuous
Subcutaneous Insulin Infusion (CSII) versus Multiple Daily Injection (MDI) for type
1 diabetes (DM1) through cost-utility analysis, from the perspective of the Mexican
Social Security Institute (IMSS).METHODS:We used a validated simulation model
(CORE Model), together with published literature for clinical, quality of life and
therapy effectiveness. Demographic information and incident complications for
131 patients with DM1 from the 21st Century Hospital (IMSS) were incorporated
into the simulation. Direct and indirect cost data were obtained from the IMSS and
Secretary of Health (SSA) National Economic Information. A simulation of the clin-
ical and economic consequences in a lifetime follow-up of therapy was performed.
Direct and indirect costs with a discount rate of 3% were input to the model.
RESULTS: Lifetime, treatmentwithCSII gained 8.5 quality-adjusted life years vs. 7.6
quality-adjusted life years for MDI therapy. Over 50 years of treatment, CSII versus
MDI, had an incremental direct cost of 422,187 Mexican Pesos (MXP) per quality
adjusted life year (QALY). For indirect costs, CSII is cost saving relative to MDI
(saving 158,831 MXP/QALY). For combined direct and indirect costs, the incremen-
tal cost-effectiveness ratio for CSII vs. MDIwas 283,356MXP/QALY.CONCLUSIONS:
Better glycemic control, and increased quality of life for DM1 patients treated with
CSII demonstrated incremental cost effectiveness below the willingness to pay
threshold set by the World Health Organization (510,300 MXP). This makes CSII a
cost effective treatment alternative to MDI in Mexico. The higher incremental di-
rect cost of CSII relative to MDI is compensated by the savings in indirect costs.
MEDICAL DEVICE/DIAGNOSTICS – Patient-Reported Outcomes & Patient
Preference Studies
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OBJECTIVES: Back and leg pain arising from spinal stenosis with degenerative
spondylolisthesis have a substantial impact on the quality of life of patients. Using
data on collected costs, resource utilization, and patient-reported outcomes from
an ongoing randomized clinical trial comparing a novel, motion-preserving inter-
laminar stabilization device (coflex®) to control (instrumented posterolateral spi-
nal fusion) among patients with spinal stenosis and spondylolisthesis, we report
and compare the relative cost-effectiveness of these two treatments.METHODS: A
model was developed to compare interventions. The primary source for the mod-
el’s clinical input parameterswas the recent investigational clinical trial of coflex®,
supporting premarket approval application to FDA. Treatment patterns over five
years were estimated based on claims data analyses and expert opinion. Oswestry
Disability Index scores collected during the trial were converted to utilities. A third-
party payer perspective was used, and costs (US 2011$) and outcomes were dis-
counted at 3% annually. Both Medicare and private-payer costs were modeled.
Sensitivity analyses examined the influence of costs, utilities, and discount rates.
RESULTS: Patients receiving coflexhadhigher success rates and lower costs in both
theMedicare and private payermodels. Payments over five yearswere estimated at
$14,534 for coflex® implant patients compared to $25,620 for controls (Medicare
costs; $17,714 vs. $31,747 for private coverage). Utilities were higher for coflex®-
treated patients at all assessments, and totaled 3.03 quality-adjusted life years
(QALY) compared to 2.98 for controls. Incremental cost-effectiveness could not be
calculated, as the novel implant dominated, demonstrating both lower costs and
better outcomes. Sensitivity analyses identified no scenario in which fusion was
preferred over the coflex®. CONCLUSIONS: The use of coflex® to treat stenosis and
spondylolisthesis is cost saving, and associated with improved patient outcomes.
Subgroup analyses comparing indications and patient characteristics should be
conducted to confirm robustness of findings.
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OBJECTIVES: Current multiple sclerosis (MS) disease modifying medications fre-
quently require the use of self-injection devices. These can present varied burdens
for patients in terms of their portability, complexity in preparation and potential
for causing discomfort. Furthermore, the necessity to self-inject is closely associ-
atedwith levels of adherence to treatment and optimising the acceptability of such
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